Samsung Bioepis secures EC approval to market RA biosimilar Flixabi in EU

Samsung Bioepis, a joint venture between Samsung BioLogics and Biogen, has secured approval from the European Commission (EC) to market rheumatoid arthritis (RA) biosimilar, Flixabi, in the European Union (EU).
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news